Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Efficacy and Safety of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

NCT07700875 is registered in ClinicalTrials.gov with Wuhan Createrna Science and Technology Co., Ltd as lead sponsor.

NCT NCT07700875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07700875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Efficacy and Safety of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
Lead sponsor
Wuhan Createrna Science and Technology Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
December 29, 2022
Completion date
September 11, 2023
Enrollment
391 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension